BriaCell Therapeutics (BCT) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing novel immunotherapies for cancer, with lead programs in metastatic breast cancer and preclinical assets in prostate cancer and other indications.

• Lead candidate Bria-IMT™ is in a pivotal Phase 3 trial for metastatic breast cancer, with FDA Fast Track designation; additional programs include Bria-OTS™, a personalized off-the-shelf immunotherapy, and Bria-PROS+™ for prostate cancer.

• Recent clinical data show promising efficacy and safety in heavily pre-treated and ADC-resistant breast cancer patients, including those with CNS metastases.

• Collaborations with Incyte and BeiGene for checkpoint inhibitors in combination studies; ongoing expansion into additional cancer types.

Financial performance and metrics

• For the nine months ended April 30, 2025: operating loss of $18.7M, net loss of $18.4M, and cash and cash equivalents of $12.5M (actual) and $30.5M (as adjusted for offering proceeds).

• As of April 30, 2025, total assets were $17.0M (actual) and $35.0M (as adjusted); shareholders' equity was $11.9M (actual) and $30.0M (as adjusted).

• Net loss per share for the nine months ended April 30, 2025 was $(6.70); weighted average shares outstanding was 2,717,927.

Use of proceeds and capital allocation

• Estimated net proceeds of $18.04M (assuming full sale at $2.93 per unit) to be used for working capital, general corporate purposes, and advancement of business objectives.

• Management has broad discretion over use of proceeds; no minimum offering amount required.